Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. - Wikidata - wikimedia - TriplyDB

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

http://www.wikidata.org/entity/Q33364244

about

The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?Modulatory effects of bortezomib on host immune cell functions Advances in the understanding of mechanisms and therapeutic use of bortezomib Development and characterization of a Mantle Cell Lymphoma Cell Bank in the American Type Culture Collection Mantle cell lymphoma: observation to transplantation PERK Integrates Oncogenic Signaling and Cell Survival During Cancer Development The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors Targeting the UPS as therapy in multiple myeloma.Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group.A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma.Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma.Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysis BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma.A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors The treatment of traumatic brain injury with velcade.A novel insertion ins(18;5)(q21.1;q31.2q35.1) in acute myeloid leukemia associated with microdeletions at 5q31.2, 5q35.1q35.2 and 18q12.3q21.1 detected by oligobased array comparative genomic hybridization Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.Targeted therapy in lymphoma.Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells.Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent

P2860

Q26772907-185850C6-F7D0-4B93-9D4D-25D7B9F93D3E Q26795618-9C1211DA-F68B-406D-8527-980438444E43 Q26849940-69CB4DEB-D1EB-44EC-AEF5-3646E204B48C Q27913808-7633D8B1-561B-4D28-8476-8D8D5FBB9126 Q28256317-A0DC0BEA-A6C3-4A13-B26D-D20CAC89865A Q28397172-0C21423C-E9CA-4AAA-BCEC-AC660D49FD5D Q30248842-A92741DE-58D9-474D-9DEC-14AD90D41D05 Q33303627-4B906ECB-E9E5-4F94-B225-0EB48A7A35F7 Q33375800-6B83A211-62E7-4AC6-AF27-0097D454329D Q33378902-5E49AFB6-CE41-4145-8664-715D590D243E Q33384287-51CB2A2B-8D76-4DF5-9CFF-E8305C130629 Q33385670-DBA364BE-A8CE-4E5E-BFC0-577244AB8263 Q33391725-AF258C8F-61BC-452C-B030-032C7FB2F023 Q33394873-4FF87529-CDFD-4EEA-AAB1-2AEDFF7A0AB1 Q33396522-2E4218F6-84B0-4558-93E5-1B21D9CFEA0A Q33404090-C87ADE6C-9728-4352-8A5A-AE4669FF907C Q33414243-9636065F-2269-4CD7-9831-E4F61CD347D3 Q33414307-1D3CB471-F241-44EF-B930-2B5CC17BA350 Q33416533-C776B24A-B591-40A2-9C72-558AD934798D Q33418257-097B8ECA-10A4-41D9-8FFC-A018823A17B0 Q33427510-C94632CA-B109-4437-B706-FC3832C0CD81 Q33443555-E4188707-1228-4647-A7D7-2CB988860058 Q33586239-C10704B8-267F-48FA-B86D-B9DCEBAA5103 Q33669018-51D98D87-5EA4-4257-8DDC-5F320BFDC77D Q33713106-5C6244EF-350B-4597-9922-B87EA26A9B37 Q34041311-B319ED99-F693-4E38-A441-EF8F3361915C Q34059058-30D4F5FD-20FA-4C8C-97D0-877EB24083CB Q34129360-BCB48BD3-CEF6-411B-8B57-510EFE5BB154 Q34134986-73BA0577-22F6-46BC-9908-D7564EC5A68B Q34218976-C27F3301-911D-41B1-A125-CC6A8D153A91 Q34254813-3A8E8A49-DB47-4A3A-B34E-11ED65170565 Q34268171-0BD95B51-13A6-45B8-AEE8-9357713C891E Q34335445-1ADDFED5-DC0D-4A2D-AC00-20BEED5F1BFE Q34372977-7C7778D0-55AE-422E-A5A7-A4F8D47EC2B7 Q34413686-D9A256CA-DA39-47A7-B98F-4913A7CCBB09 Q34541718-B2A5B582-7706-4BAF-8506-1B79E0BCC257 Q34542087-2C27D3B4-3A8A-4BBC-86A4-226C26B173FA Q34585047-D4F93F9B-87BF-4617-B33C-93D782D724CC Q34608608-0C944D1B-A9C9-4883-ACE0-78087A79BCAE Q34610605-08DA4C4A-4A91-47C9-8850-D10359CB5348

P2860

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

http://www.wikidata.org/entity/Q33364244

description

2004 nî lūn-bûn

@nan

2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Phase II clinical experience w ...... homa and mantle cell lymphoma.

@ast

Phase II clinical experience w ...... homa and mantle cell lymphoma.

@en

type

label

Phase II clinical experience w ...... homa and mantle cell lymphoma.

@ast

Phase II clinical experience w ...... homa and mantle cell lymphoma.

@en

prefLabel

Phase II clinical experience w ...... homa and mantle cell lymphoma.

@ast

Phase II clinical experience w ...... homa and mantle cell lymphoma.

@en

P1433

Q33364244-62BB1F63-7A85-4756-A4A0-EC805E0F061A

P1476

Q33364244-639267DE-D32F-485D-83CF-9E07F1465BEA

P2093

Q33364244-14ABA9E6-E093-406B-BC80-A1725233BCC3

Q33364244-354BA196-DC90-47BB-8151-CAA41215E957

Q33364244-3DB28CDA-B35C-4BAB-BAA6-99C2222DA872

Q33364244-4E7DFB49-A934-47D8-81AA-7F81F05362B9

Q33364244-56603DC9-3ED2-421C-99F5-43E854142D13

Q33364244-58ABD3C6-E159-4D91-9069-664F29361F06

Q33364244-6965B937-D8A9-4D99-8279-F4E1F61D3D4A

Q33364244-6CBEF8ED-EC79-4F38-8F8B-EE80A297C3B2

Q33364244-77CE5F1B-7D40-473C-A590-60B04002316A

Q33364244-A69A41E1-F040-4AD8-91B8-284B33187CAC

P304

Q33364244-6B7CB44F-CB46-4976-B466-C02CA104AF69

P31

Q33364244-81D3ACBF-FD0B-4BC4-84E8-B5D963200920

P356

Q33364244-337E1B06-1ECB-41DA-B614-09BA180C495A

P407

Q33364244-6BAD729F-30C6-46B0-B7CC-BB21D0B0B638

P433

Q33364244-B82927CB-2638-4A6A-A7EF-323035BE1DB5

P478

Q33364244-50F487DF-0CDD-426C-A9B7-DC46A0A01240

P50

Q33364244-05B0CE76-2481-4B28-AD8A-23308090AF22

Q33364244-42742025-ACF9-4322-AF06-E26811ABA9BD

P577

Q33364244-A746ED2F-97C3-4C5F-8FA6-B1791C46A420

P698

Q33364244-18E06421-E76F-43BA-8152-9834279A7A93

P921

Q33364244-6292AA13-E847-4D7B-937E-3B33B4C9FCB1

P356

JCO.2005.02.050

P1433

Journal of Clinical Oncology

P1476

Phase II clinical experience w ...... homa and mantle cell lymphoma.

@en

P2093

Barbara MacGregor-Cortelli

http://www.w3.org/2001/XMLSchema#string

Carol Portlock

http://www.w3.org/2001/XMLSchema#string

Craig Moskowitz

http://www.w3.org/2001/XMLSchema#string

David Schenkein

http://www.w3.org/2001/XMLSchema#string

David Straus

http://www.w3.org/2001/XMLSchema#string

Dixie Esseltine

http://www.w3.org/2001/XMLSchema#string

Elizabeth Choi

http://www.w3.org/2001/XMLSchema#string

Elizabeth Trehu

http://www.w3.org/2001/XMLSchema#string

Jamie Muzzy

http://www.w3.org/2001/XMLSchema#string

John Wright

http://www.w3.org/2001/XMLSchema#string

P304

676-684

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.02.050

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Andrew D Zelenetz

P577

2004-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15613699

http://www.w3.org/2001/XMLSchema#string

P921